This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.



Drug Names(s): TG101348, SAR503, SAR302503

Description: SAR302503 is an oral, highly selective JAK2 inhibitor.

Deal Structure: TG101348 was originally developed by TargeGen.

Sanofi and TargeGen
In June 2010, sanofi-aventis announced that it signed an agreement for the acquisition of TargeGen. Under the terms of the agreement, sanofi-aventis will make an upfront payment of US $75 million upon closing of the transaction. Further milestones payments will occur at different stages of development of TargeGen's lead product, TG 101348. The total amount of all payments, including the upfront payment, could reach US $560 million.

Fedratinib News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug